Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial

BACKGROUND: Irbesartan, a long acting selective angiotensin-1 receptor inhibitor, in Marfan syndrome might reduce aortic dilatation, which is associated with dissection and rupture. We aimed to determine the effects of irbesartan on the rate of aortic dilatation in children and adults with Marfan sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Mullen, Michael, Jin, Xu Yu, Child, Anne, Stuart, A Graham, Dodd, Matthew, Aragon-Martin, José Antonio, Gaze, David, Kiotsekoglou, Anatoli, Yuan, Li, Hu, Jiangting, Foley, Claire, Van Dyck, Laura, Knight, Rosemary, Clayton, Tim, Swan, Lorna, Thomson, John D R, Erdem, Guliz, Crossman, David, Flather, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934233/
https://www.ncbi.nlm.nih.gov/pubmed/31836196
http://dx.doi.org/10.1016/S0140-6736(19)32518-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934233/
https://www.ncbi.nlm.nih.gov/pubmed/31836196
http://dx.doi.org/10.1016/S0140-6736(19)32518-8

Ejemplares similares